baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

IDORSIA N/ CH0363463438 /

2024-10-08 5:30:17 PM	Chg. +0.0370	Volume	Bid6:39:13 PM	Ask6:39:13 PM	Market Capitalization	Dividend Y.	P/E Ratio
1.4330CHF	+2.65%	343,518 Turnover: 480,084.0685	1.4500Bid Size: 5,000	1.4330Ask Size: 700	270.09 mill.CHF	-	-

GlobeNewswire 08-13 Santhera Closes Financings and Secures Funds to Reach Break-Even Expected in 2026

GlobeNewswire 08-09 Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2...

GlobeNewswire 06-24 Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

GlobeNewswire 06-18 Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow ...

GlobeNewswire 05-22 Invivyd Elects Two New Independent Members to its Board of Directors

GlobeNewswire 05-09 Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024

GlobeNewswire 04-17 Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determ...

GlobeNewswire 04-01 Nxera Pharma is the New Name for Sosei Group

GlobeNewswire 03-27 Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of C...

GlobeNewswire 02-28 Idorsia and Viatris enter into a significant global research and development collaboration

GlobeNewswire 02-16 Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Offic...

GlobeNewswire 02-13 Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

GlobeNewswire 01-22 Sosei Heptares Webinar Presentation for FY2023 Financial Results

GlobeNewswire 01-05 Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief O...

GlobeNewswire 2023-12-07 Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea

GlobeNewswire 2023-11-15 Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

GlobeNewswire 2023-11-10 Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine ...

GlobeNewswire 2023-11-03 New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at th...

GlobeNewswire 2023-10-31 Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), ...

GlobeNewswire 2023-10-25 Sosei Heptares to Host R&D Day Highlighting its Innovative R&D and Late-Stage Development Progress

GlobeNewswire 2023-10-16 CRISPR Therapeutics Proposes New Appointment to the Board of Directors

GlobeNewswire 2023-09-11 Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Of...

GlobeNewswire 2022-02-28 Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference

GlobeNewswire 2022-02-17 Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results

GlobeNewswire 2022-02-08 Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profit...

IDORSIA N/ CH0363463438 /

If you wish to receive reply to your feedback, please provide your email address.